公开(公告)号：US20210317453A1

公开(公告)日：2021-10-14

申请号：US17268174

申请日：2019-08-13

Applicant: CancerStem Tech Inc.

Inventor： Masaki MORI ,  Hirofumi YAMAMOTO ,  Xin WU

IPC: C12N15/113 ,  A61K45/06 ,  A61P35/00 ,  C07K16/30 ,  G01N33/574

Abstract: The present invention provides a cancer stem cell elimination agent containing a substance that suppresses an expression or function of SDC4, a method for detecting or sorting a cancer stem cell in a cancer cell population, including using an expression of SDC4 as an index, and the like.

公开(公告)号：US20210052627A1

公开(公告)日：2021-02-25

申请号：US16498986

申请日：2018-03-30

Applicant: CancerStem Tech Inc.

Inventor： Xin Wu ,  Masaki Mori ,  Hirofumi Yamamoto

IPC: A61K31/7105 ,  A61P35/00 ,  C12N15/113

Abstract: The purpose of the present invention is to provide a nucleic acid medication for cancer treatment, the medication being capable of suppressing the growth of cancer stem cells and thus effectively treating cancer. hsa-miR-136-5p, hsa-miR-3065-3p, hsa-miR-4727-5p, hsa-miR-378g, hsa-miR-181a-5p, hsa-miR-362-5p, and hsa-miR-608 have remarkably excellent growth inhibitory action on cancer stem cells and are thus useful as a nucleic acid medication for the treatment of various cancers.

公开(公告)号：US11439657B2

公开(公告)日：2022-09-13

申请号：US16498986

申请日：2018-03-30

Applicant: CancerStem Tech Inc.

Inventor： Xin Wu ,  Masaki Mori ,  Hirofumi Yamamoto

IPC: C07H21/02 ,  C07H21/04 ,  A61K31/7105 ,  A61P35/00 ,  C12N15/113 ,  A61K45/06

Abstract: The purpose of the present invention is to provide a nucleic acid medication for cancer treatment, the medication being capable of suppressing the growth of cancer stem cells and thus effectively treating cancer. hsa-miR-136-5p, hsa-miR-3065-3p, hsa-miR-4727-5p, hsa-miR-378g, hsa-miR-181a-5p, hsa-miR-362-5p, and hsa-miR-608 have remarkably excellent growth inhibitory action on cancer stem cells and are thus useful as a nucleic acid medication for the treatment of various cancers.

公开(公告)号：US20220241315A1

公开(公告)日：2022-08-04

申请号：US17596137

申请日：2020-05-29

Applicant: CancerStem Tech Inc. ,  OSAKA UNIVERSITY

Inventor： Hirofumi Yamamoto ,  Xin Wu

IPC: A61K31/713 ,  A61P35/00

Abstract: An object of the present invention is to provide a nucleic acid medicine for cancer treatment that makes it possible to treat cancer effectively. miR-4711-5p can suppress the expression of KLF5, TFDP1, and MDM2, as a result suppressing the proliferation, infiltration, and migration of cancer cells effectively, inducing apoptosis and G1 arrest, and also lowering stemness.

公开(公告)号：US20200040307A1

公开(公告)日：2020-02-06

申请号：US16499094

申请日：2018-03-30

Applicant: CancerStem Tech Inc.

Inventor： Xin Wu ,  Masaki Mori ,  Hirofumi Yamamoto

IPC: C12N5/095 ,  C12N15/86 ,  G01N33/15 ,  G01N33/50

Abstract: The purpose of the present invention is to provide: a cancer stem cell having an excellent ability to form tumor tissue; and a method for establishing the cancer stem cell. Cells having a low metabolic function of 26S proteasome are isolated and concentrated from a cancer stem cell group containing cancer stem cells, thereby obtaining cancer stem cells which can form tumor tissue in a living body even when the number of cells is 200 or less.